These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 31666296)

  • 61. Phage choice, isolation, and preparation for phage therapy.
    Gill JJ; Hyman P
    Curr Pharm Biotechnol; 2010 Jan; 11(1):2-14. PubMed ID: 20214604
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Possibilities of bacteriophage therapy].
    Skurnik M; Kiljunen S
    Duodecim; 2016; 132(8):712-9. PubMed ID: 27244930
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Phage therapy, an alternative to antibiotic therapy?)].
    Reina J; Reina N
    Rev Esp Quimioter; 2018 Apr; 31(2):101-104. PubMed ID: 29451376
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy.
    Segall AM; Roach DR; Strathdee SA
    Curr Opin Microbiol; 2019 Oct; 51():46-50. PubMed ID: 31226502
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Controlled phage therapy by photothermal ablation of specific bacterial species using gold nanorods targeted by chimeric phages.
    Peng H; Borg RE; Dow LP; Pruitt BL; Chen IA
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):1951-1961. PubMed ID: 31932441
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Novel Bacteriophage with Broad Host Range against Clostridioides difficile Ribotype 078 Supports SlpA as the Likely Phage Receptor.
    Whittle MJ; Bilverstone TW; van Esveld RJ; Lücke AC; Lister MM; Kuehne SA; Minton NP
    Microbiol Spectr; 2022 Feb; 10(1):e0229521. PubMed ID: 35107319
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Implications of lytic phage infections inducing persistence.
    Sanchez-Torres V; Kirigo J; Wood TK
    Curr Opin Microbiol; 2024 Jun; 79():102482. PubMed ID: 38714140
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Review article: bacteriophages in gastroenterology-from biology to clinical applications.
    Sabino J; Hirten RP; Colombel JF
    Aliment Pharmacol Ther; 2020 Jan; 51(1):53-63. PubMed ID: 31696976
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bacteriophage-host arm race: an update on the mechanism of phage resistance in bacteria and revenge of the phage with the perspective for phage therapy.
    Azam AH; Tanji Y
    Appl Microbiol Biotechnol; 2019 Mar; 103(5):2121-2131. PubMed ID: 30680434
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review.
    Chegini Z; Khoshbayan A; Vesal S; Moradabadi A; Hashemi A; Shariati A
    Ann Clin Microbiol Antimicrob; 2021 Apr; 20(1):30. PubMed ID: 33902597
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections.
    Bodier-Montagutelli E; Morello E; L'Hostis G; Guillon A; Dalloneau E; Respaud R; Pallaoro N; Blois H; Vecellio L; Gabard J; Heuzé-Vourc'h N
    Expert Opin Drug Deliv; 2017 Aug; 14(8):959-972. PubMed ID: 27776446
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Diverse Impacts of Phage Morons on Bacterial Fitness and Virulence.
    Taylor VL; Fitzpatrick AD; Islam Z; Maxwell KL
    Adv Virus Res; 2019; 103():1-31. PubMed ID: 30635074
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage?
    Hesse S; Adhya S
    Annu Rev Microbiol; 2019 Sep; 73():155-174. PubMed ID: 31185183
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bacteriophages and bacterial extracellular vesicles, threat or opportunity?
    Meidaninikjeh S; Mohammadi P; Elikaei A
    Life Sci; 2024 Aug; 350():122749. PubMed ID: 38821215
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences.
    Chanishvili N
    Curr Drug Deliv; 2016; 13(3):309-23. PubMed ID: 27090515
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preclinical data and safety assessment of phage therapy in humans.
    Nale JY; Clokie MR
    Curr Opin Biotechnol; 2021 Apr; 68():310-317. PubMed ID: 33862490
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phage Therapy Is Effective in a Mouse Model of Bacterial Equine Keratitis.
    Furusawa T; Iwano H; Hiyashimizu Y; Matsubara K; Higuchi H; Nagahata H; Niwa H; Katayama Y; Kinoshita Y; Hagiwara K; Iwasaki T; Tanji Y; Yokota H; Tamura Y
    Appl Environ Microbiol; 2016 Sep; 82(17):5332-9. PubMed ID: 27342558
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Framing the Future with Bacteriophages in Agriculture.
    Svircev A; Roach D; Castle A
    Viruses; 2018 Apr; 10(5):. PubMed ID: 29693561
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Characterization of four virulent Klebsiella pneumoniae bacteriophages, and evaluation of their potential use in complex phage preparation.
    Zurabov F; Zhilenkov E
    Virol J; 2021 Jan; 18(1):9. PubMed ID: 33407669
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phage therapy--constraints and possibilities.
    Nilsson AS
    Ups J Med Sci; 2014 May; 119(2):192-8. PubMed ID: 24678769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.